Myriad Genetics, Inc. announced that its MyRisk® Hereditary Cancer Test with RiskScore® was recognized in the American Journal of Human Genetics as one of the top 10 significant advances in ...

Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...

MYGN Stock’s Likely Trend Following the News After the announcement yesterday, Myriad Genetic shares edged up 0.8% in the after-hours trading. With MyRisk expected to continue its strong growth ...

Myriad Genetics’ MyRisk Hereditary Cancer test and somatic tumor profiling MyChoice CDx test were previously certified by the New York State Department of Health. TheraMap is the first test in ...

Myriad Genetics. Myriad’s Breast Cancer Risk Assessment Program features the MyRisk ® with RiskScore ® Hereditary Cancer Test, the first and industry-leading hereditary cancer test and polygenic ...

Research analysts at Leerink Partnrs boosted their FY2024 EPS estimates for Myriad Genetics in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that ...

The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...

SAN FRANCISCO — At the JP Morgan Healthcare Conference here on Wednesday, Myriad Genetics CEO Paul Diaz provided preliminary Q4 and full-year 2024 financial results, as well as full-year 2025 guidance ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at ...

SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed ...